Skip to main content
Bloomberg Law

How Life Sciences Firms Can Reduce DOJ Enforcement Risks

May 6, 2021
Authors
Jaime L.M. JonesJack W. Pirozzolo

The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.

View Article

Contacts

Jones, Jaime L.M.
Partner
Pirozzolo, Jack W.
Partner

Related Blogs

Capabilities

Suggested News & Insights

Sidley Lawyers Jaime Jones, Jennifer Saulino, and Lisa Miller to Speak at the ABA′s 2026 Qui Tam & Civil False Claims and Healthcare Fraud Institute in Washington, D.C.Wednesday, May 27, 2026 – Thursday, May 28, 2026
Speaking Engagements
Tariff Enforcement at the Forefront: Importer Agrees to Pay $549.5 million in Largest-Ever Trade-Related False Claims Act SettlementMay 18, 2026
Original Source
The First Prediction Market Insider Trading Case: SDNY and CFTC Test the Limits of Fraud and Commodities LawMay 13, 2026
White Collar Defense and Investigations Update
DOJ’s National Fraud Enforcement Division Launches West Coast Health Care Fraud Strike ForceMay 6, 2026
Original Source
E.D. Pa. Rejects Indefinite Sealing of FCA Extension Materials, Emphasizing Narrow Purpose of SealMay 5, 2026
Original Source
Texas Qui Tam Under Fire: Texas Appellate Dissent Raises Major Constitutional DoubtsMay 4, 2026
Original Source